Elicit: Pharmacokinetics and Pharmacodynamics of Emicizumab in Hemophilia A
Pharmacokinetics and Pharmacodynamics of Emicizumab in Hemophilia A
Emicizumab exhibits predictable, dose-proportional pharmacokinetics with sustained plasma concentrations that produce FVIII-equivalent hemostatic activity and reduce bleeding rates by 94% through an exposure-response relationship plateauing above 30 µg/mL.
Abstract
Emicizumab demonstrates dose-proportional, predictable pharmacokinetics across diverse hemophilia A populations, with subcutaneous administration achieving sustained trough concentrations of 42-66 µg/mL during maintenance dosing across weekly (1.5 mg/kg), every-2-weeks (3 mg/kg), and every-4-weeks (6 mg/kg) regimens. The median elimination half-life is 23-30 days, with time to steady-state of 12 weeks with loading doses and 24 weeks without. Interindividual variability in trough concentrations is moderate (32%), influenced primarily by body weight, age, albumin levels, and rarely by neutralizing antibodies. Infants achieve higher concentrations (60-65 µg/mL) than older individuals with identical dosing, while bioavailability decreases after age 65. Pharmacodynamically, emicizumab maintains FVIII-equivalent activity of 17-25 IU/dL, thrombin generation >100 nM, and normalized aPTT without affecting FIX, FX, or coagulation activation markers.
Exposure-response modeling establishes that bleeding control plateaus above emicizumab concentrations of 30 µg/mL (IC50 3.58 µg/mL), explaining equivalent efficacy across dosing regimens that achieve mean concentrations of 53.5 µg/mL and produce a 94% reduction in annualized bleeding rates. Clinical studies demonstrate annualized bleeding rates for treated bleeds of 0.4-2.4, with 54-78% of patients achieving zero treated bleeds. The safety profile is favorable, with injection site reactions as the most common adverse event (16-22%), no thromboembolic events when used alone, and minimal immunogenicity. These pharmacokinetic and pharmacodynamic characteristics support body weight-based dosing without routine therapeutic drug monitoring, with potential for individualized dosing in patients maintaining concentrations substantially above the 30 µg/mL efficacy threshold.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. More on methods
Screening
We screened in sources based on their abstracts that met these criteria:
- Population - Hemophilia A: Does the study include patients diagnosed with hemophilia A?
- Intervention - Emicizumab: Does the study investigate emicizumab as the primary intervention?
- Outcome - PK/PD Data: Does the study report pharmacokinetic data (e.g., plasma concentrations, clearance, half-life, bioavailability) and/or pharmacodynamic data (e.g., factor VIII mimetic activity, bleeding rates, coagulation parameters)?
- Study Population - Human Subjects: Is the study conducted in human subjects (not animal or in vitro studies)?
- Study Design: Is the study a clinical trial (Phase I, II, III, IV), observational study, case series, case report, systematic review, or meta-analysis?
- Intervention Specificity: Does the study include emicizumab as an intervention (not focusing solely on other hemophilia treatments without emicizumab)?
- Population Specificity: Does the study include hemophilia A participants (not exclusively patients with hemophilia B or other bleeding disorders without any hemophilia A participants)?
- Data Relevance: Does the study report pharmacokinetic and/or pharmacodynamic data (not only clinical efficacy or safety outcomes without PK/PD data)?
Results
Characteristics of Included Studies
The review included 10 sources examining emicizumab pharmacokinetics and pharmacodynamics in hemophilia A, comprising clinical trial reports, a systematic review, and an exposure-response modeling study. The studies varied in design from Phase I dose-escalation trials to Phase III pivotal studies and represented diverse patient populations.
| Study | Full text retrieved? | Study Type | Population | Sample Size (PK/PD) | Study Design |
|---|---|---|---|---|---|
| C. Schmitt et al., 2020 | Yes | Primary study (Phase III) | Adults/adolescents (12-75 years) with severe HA and FVIII inhibitors; multicenter (14 countries) | 112 | Open-label, multicenter, randomized |
| A. Kiialainen et al., 2023 | No (abstract only) | Pooled analysis | HAVEN 1-4 participants | Not specified | Phase III trials |
| M. Shima et al., 2016 | No (abstract only) | Primary study (Phase I) | Japanese adults with severe HA with/without inhibitors | 18 | Open-label, non-randomized, dose-escalation |
| M. Shima et al., 2017 | Yes | Primary study (Phase I/II extension) | Japanese adults (12-58 years) with severe HA with/without inhibitors | 18 | Open-label, long-term extension |
| S. Pipe et al., 2022 | No (abstract only) | Primary study (Phase IIIb interim) | Infants ≤12 months with severe HA without inhibitors | 52 | Multi-center, open-label (HAVEN 7) |
| Qianqian Mao et al., 2025 | No (abstract only) | Primary study (retrospective) | Chinese pediatric patients (0.93-16.25 years) with HA | 46 | Retrospective single-center |
| S. Pipe et al., 2023 | No (abstract only) | Primary study (Phase IIIb primary) | Infants ≤12 months with severe HA without inhibitors | 55 | Multi-center, open-label (HAVEN 7) |
| A. Donners et al., 2021 | Yes | Systematic review | Adults and children (0 to ≥12 years) with HA with/without inhibitors | 469 PwHA, 140 volunteers | Systematic review of 15 studies |
| S. Pipe et al., 2019 | No (abstract only) | Primary study (Phase III) | Adults/adolescents (≥12 years) with severe HA with/without inhibitors from 6 countries | 41 (expansion cohort) | Multi-center, open-label, two-stage (HAVEN 4) |
| F. Jonsson et al., 2021 | Yes | Modeling study | 445 PwHA with/without inhibitors (age 1-77 years) | 385 emicizumab-treated | Exposure-response modeling of pooled Phase III data |
Dosing Regimens and Administration
Emicizumab was administered subcutaneously across all studies, with various loading and maintenance regimens tested to optimize pharmacokinetic profiles.
| Study | Loading Dose | Maintenance Dose | Dosing Frequency | Duration |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg | Once weekly | Median 60.5 weeks (range 3.3-94.2) |
| A. Kiialainen et al., 2023 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Weekly, Q2W, or Q4W | Not specified |
| M. Shima et al., 2016 | None mentioned | 0.3, 1.0, or 3.0 mg/kg | Weekly | 12 weeks |
| M. Shima et al., 2017 | 1 mg/kg (cohort 1), 3 mg/kg (cohort 2) | 0.3, 1.0, or 3.0 mg/kg | Once weekly | Up to 33.3 months |
| S. Pipe et al., 2022 | 3 mg/kg weekly for 4 weeks | 3 mg/kg | Every 2 weeks for 52 weeks | ≥52 weeks with 7-year follow-up |
| Qianqian Mao et al., 2025 | Median 2.85 mg/kg per week (range 2.14-3.90) | Median 5.21 mg/kg (range 2.54-6.46) | Loading: weekly; Maintenance: every 28 days | December 2023-July 2025 |
| S. Pipe et al., 2023 | 3 mg/kg weekly for 4 weeks | 3 mg/kg, 1.5 mg/kg, or 6 mg/kg | Q2W for 52 weeks; then weekly or Q4W options | ≥52 weeks with 7-year follow-up |
| A. Donners et al., 2021 | Not mentioned | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Weekly (75%), Q2W (11%), Q4W (14%) | ≥16 weeks |
| S. Pipe et al., 2019 | 3 mg/kg weekly for 4 weeks | 6 mg/kg | Every 4 weeks | ≥24 weeks |
| F. Jonsson et al., 2021 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Once weekly, Q2W, or Q4W | 365.25 days for ABR calculation |
Pharmacokinetic Parameters
Emicizumab demonstrated predictable, dose-proportional pharmacokinetics across diverse patient populations.
Plasma Concentrations
| Study | Steady-State Trough Concentrations | Peak/Loading Concentrations | Time to Steady-State |
|---|---|---|---|
| C. Schmitt et al., 2020 | ≥50 µg/mL maintained; mean 54.1 µg/mL after loading, sustained >50 µg/mL | Not specified | Not specified |
| A. Kiialainen et al., 2023 | 42.1-52.3 µg/mL with maintenance dosing | Mean 52.9 µg/mL (SD 13.6) at week 5 | Not specified |
| M. Shima et al., 2016 | Increased in dose-dependent manner | Not specified | Not specified |
| M. Shima et al., 2017 | 10.3 mg/mL (cohort 1), 29.9 mg/mL (cohort 2), 120 mg/mL (cohort 3) | Not specified | ~12 weeks with loading, 24 weeks without |
| S. Pipe et al., 2022 | 60-65 µg/mL maintained | Mean 63.2 µg/mL (95% CI: 59.5-66.8) at Week 5 | Not specified |
| Qianqian Mao et al., 2025 | Maintenance: median 50.6 µg/mL (range 17.3-81.7) | Loading: median 57.7 µg/mL (range 31.8-79.9) | Not specified |
| S. Pipe et al., 2023 | Sustained at 57-66 µg/mL | Mean 62.0 µg/mL (95% CI: 58.3-65.6) at Week 5 | Not specified |
| A. Donners et al., 2021 | Moderate interindividual variability (32%) | Not specified | Not specified |
| S. Pipe et al., 2019 | Not specified | Not specified | Not specified |
| F. Jonsson et al., 2021 | ~50 µg/mL across regimens; trough: 28.4 (QW), 24.9 (Q2W), 17.7 (Q4W) µg/mL | Not specified | Not specified |
Pharmacokinetic Variability
Interindividual variability in trough concentrations was moderate at 32% and remained consistent across various subgroups including FVIII inhibitor status, age group, and dosing interval. Total PK interindividual variability was approximately 60%, influenced by body weight, neutralizing antidrug antibodies, age, and albumin levels.
Pharmacodynamic Outcomes
FVIII-Equivalent Activity and Coagulation Parameters
| Study | FVIII-Equivalent Activity (IU/dL) | aPTT Response | Thrombin Generation (nM) | Other Coagulation Parameters |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | Remained above 20 U/dL | Normalized at subtherapeutic concentrations | Peak height above 100 nM | FIX, FX, fibrinogen, PT, D-dimer, PF1.2 not significantly affected |
| A. Kiialainen et al., 2023 | 25.2 IU/dL at week 5, sustained 17-23 IU/dL | Shortened following first dose | 115.2 nM at week 5, sustained >116 nM | Not mentioned |
| M. Shima et al., 2016 | Not mentioned | Remained short throughout | Not mentioned | No clinically relevant coagulation abnormalities |
| M. Shima et al., 2017 | Not mentioned | Remained short, within or shorter than reference range | Promotion of FXIa-triggered thrombin generation | Not mentioned |
| S. Pipe et al., 2022 | 21 U/dL during loading, sustained | Normalized by Week 3 | Increased to 100 nM from Week 17 onwards | FIX and FX unaffected |
| Qianqian Mao et al., 2025 | Loading: 14.6 IU/dL (range 7.4-39.2); Maintenance: 20.2 IU/dL (range 8.9-39.6) | Not mentioned | Not mentioned | Not mentioned |
| S. Pipe et al., 2023 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| A. Donners et al., 2021 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| S. Pipe et al., 2019 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
Bleeding Outcomes
| Study | Treated Bleeds ABR (95% CI) | All Bleeds ABR (95% CI) | Treated Joint Bleeds ABR (95% CI) | Zero Treated Bleeds (%) |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | 87% reduction vs. no prophylaxis | Not specified | Not specified | 62.9% |
| M. Shima et al., 2016 | Cohort 1: 32.5→4.4; Cohort 2: 18.3→0.0; Cohort 3: 15.2→0.0 | Not specified | Not specified | 73% (with inhibitors), 71% (without) |
| M. Shima et al., 2017 | Median: Cohort 1: 1.4; Cohort 2: 0.2; Cohort 3: 0 | Not specified | Not specified | 8/18 patients (44%) |
| S. Pipe et al., 2022 | 0.4 (0.23-0.65) | 1.9 (1.35-2.68) | 0.1 (0.01-0.22) | 77.8% |
| Qianqian Mao et al., 2025 | Median ABR: 0 | Not specified | Not specified | Not specified |
| S. Pipe et al., 2023 | 0.4 (0.30-0.63) | 2.0 (1.49-2.66) | 0.0 (0.01-0.09) | 54.5% |
| A. Donners et al., 2021 | At 30 µg/mL: 2.4; At 50 µg/mL: 1.9 | Not specified | At 30 µg/mL: 1.1; At 50 µg/mL: 1.0 | 70.8%→80.2% after 1 year |
| S. Pipe et al., 2019 | 2.4 (1.4-4.3) | 4.5 (3.1-6.6) | 1.7 (0.8-3.7) | 56.1% (39.7-71.5) |
| F. Jonsson et al., 2021 | Predicted mean: 1.28 at 53.5 µg/mL (94% reduction from baseline) | Not specified | Not specified | Not specified |
Exposure-Response Relationships
Several studies characterized the relationship between emicizumab concentrations and clinical outcomes, demonstrating clear concentration-dependent effects on both pharmacodynamic biomarkers and bleeding control.
Concentration-Biomarker Correlations
FVIII-like activity and thrombin generation peak height correlated with emicizumab concentrations. The Chinese pediatric study quantified this relationship, finding a positive correlation between emicizumab concentration and FVIII-equivalent activity by linear regression (Y = 0.9569·X + 33.24, R² = 0.37, p < 0.01) and Spearman correlation (ρ = 0.56, p < 0.01). The relationship between emicizumab plasma concentration and aPTT was well described by an inhibitory Emax model.
Factors Affecting Pharmacokinetics and Pharmacodynamics
Body Weight and Size Effects
Body weight was a significant covariate affecting emicizumab pharmacokinetics across multiple studies. Dosing regimens were universally based on body weight (mg/kg), and including body weight in population PK models significantly reduced interindividual variability in both clearance (CL/F) and volume of distribution (V/F).
Age Effects
Age emerged as an important covariate affecting emicizumab pharmacokinetics and potentially pharmacodynamics. Bioavailability decreased with age, particularly after 65 years.
Safety and Immunogenicity
Emicizumab demonstrated a favorable safety profile across all studies, with most adverse events being mild and not leading to treatment discontinuation.
Summary
The pharmacokinetic and pharmacodynamic characteristics of emicizumab demonstrate remarkable consistency across diverse populations and study designs, supporting its use as a prophylactic treatment for hemophilia A.